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Translational Relevance: 
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease; some patients 
exhibit an indolent disease, while others experience a highly chemotherapy-
refractory disease, highlighting the need for prognostic markers and novel 
therapeutic approaches. B cell receptor (BCR) ligation generates signals that play a 
pivotal role in promoting progression of the leukemic clone: inhibiting the signals that 
orchestrate these events is key to disrupting disease progression. We establish that 
the mechanistic target of rapamycin (mTOR) signaling cascade is differentially 
regulated across prognostic cohorts of CLL patients and that the dual mTORC1/2 
inhibitor AZD8055 preferentially decreases viability of cells derived from poor 
prognostic CLL subsets through inhibition of mTORC2-AKT-mediated signals and 
subsequent engagement of the FOXO1-regulated molecular braking system. FOXO1 
function was further enhanced upon combination of AZD8055 with the BTK inhibitor 
ibrutinib, indicating that dual mTOR inhibitors may show promise as future CLL 
therapies, particularly in combination with ibrutinib. 
 
Statement of Significance: 
We demonstrate that the mTOR signaling cascade is differentially regulated in 
distinct prognostic CLL cohorts, and that dual mTORC1/2 inhibitors preferentially 
induce apoptosis of poor prognostic CLL subsets. Our data establish that mTORC2 
inhibition reduces AKT-mediated signals, leading to a reactivation of FOXO1-
regulated molecular braking system. 
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Abstract: 
 
PURPOSE: To determine whether inhibition of mechanistic target of rapamycin 
(mTOR) kinase-mediated signaling represents a valid therapeutic approach for 
chronic lymphocytic leukemia (CLL). 
EXPERIMENTAL DESIGN: Stratification of mTOR activity was carried out in primary 
CLL patient samples and an aggressive CLL-like mouse model. The potency of dual 
mTOR inhibitor AZD8055 to induce apoptosis in primary CLL cells was assessed in 
the presence/absence of B cell receptor (BCR) ligation. Furthermore, we addressed 
the molecular and functional impact of dual mTOR inhibition in combination with BTK 
inhibitor ibrutinib. 
RESULTS: Differential regulation of basal mTORC1 activity was observed in poor 
prognostic CLL samples, with elevated p4EBP1T37/46 and decreased p70S6 kinase 
activity, suggesting that dual mTORC1/2 inhibitors may exhibit improved response in 
poor prognostic CLL compared with rapalogs. AZD8055 treatment of primary CLL 
cells significantly reduced CLL survival in vitro compared with rapamycin, 
preferentially targeting poor prognostic subsets and overcoming BCR-mediated 
survival advantages. Furthermore, AZD8055, and clinical analog AZD2014, 
significantly reduced CLL tumor load in mice. AKT substrate FOXO1, while 
overexpressed in CLL cells of poor prognostic patients in LN biopsies, peripheral 
CLL cells, and mouse-derived CLL-like cells, appeared to be inactive. AZD8055 
treatment partially reversed FOXO1 inactivation downstream of BCR crosslinking, 
significantly inhibiting FOXO1T24 phosphorylation in an mTORC2-AKT-dependent 
manner, to promote FOXO1 nuclear localization, activity and FOXO1-mediated gene 
regulation. FOXO1 activity was further significantly enhanced on combining 
AZD8055 with ibrutinib. 
CONCLUSIONS: Our studies demonstrate that dual mTOR inhibitors show promise 
as future CLL therapies, particularly in combination with ibrutinib. 
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Introduction: 
 
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disorder of 
mature B lymphocytes, characterized by infiltration and accumulation of leukemic 
cells in lymphoid organs (1). The pathogenesis of CLL involves genetic aberrations, 
antigenic stimulation, and microenvironmental stimuli (1, 2). CLL is biologically 
heterogeneous; while some patients exhibit an indolent disease, others experience a 
highly chemotherapy-refractory disease (1), emphasizing the need for both 
prognostic markers and novel therapeutic approaches. A growing number of factors 
are recognized to have prognostic implications in CLL, with a lack of mutations in 
gene loci encoding the variable region of the immunoglobulin heavy-chain (IgVH) and 
ectopic zeta chain-associated protein kinase (ZAP-70) expression conferring poor 
outcomes (3-5). Cytogenetic aberrations are also important determinants of disease 
outcome, with deletions in chromosome 13 [del(13q)] conferring a favourable 
prognosis, while del(11q) [targeting ATM] and del(17p) [targeting TP53] are 
associated with more progressive disease (6).  Indeed, survival rates of del(17p) 
cohorts had not improved with standard chemotherapy regimens (7). 
 
The BCR has long been implicated in normal B cell development and B cell 
malignancies, with BCR ligation initiating downstream signaling cascades, via 
tyrosine kinases Lyn, SYK and BTK, such as the PI3K-AKT signaling pathway, vital 
for both normal B cell and CLL cell survival (8-10). Targeted inhibition of BCR 
signaling components, with either ibrutinib (targeting BTK) or idelalisib (targeting 
PI3K), have demonstrated increased response rates in high-risk patient cohorts (11, 
12). However, these treatments are not suitable for all CLL patients, and the 
development of drug resistance in CLL cells has been demonstrated (13), 
highlighting the need to develop alternative therapeutic options for CLL patients.  
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The serine/threonine protein kinase mechanistic target of rapamycin (mTOR), 
interacts with distinct groups of proteins to form two complexes called mTOR 
complex-1 (mTORC1: RAPTOR, mLST8, PRAS40 and DEPTOR) and complex-2 
(mTORC2: RICTOR, mLST8, mSIN1 and DEPTOR) which regulate essential cellular 
functions including cell growth, survival and proliferation (14). mTOR signaling is 
often deregulated in cancer (15), but little is known about its role in CLL 
pathogenesis. A recent clinical trial showed limited response in relapsed/refractory 
CLL patients to everolimus, a rapamycin analog (16). This is likely because rapalogs 
are allosteric inhibitors of mTORC1 only, which uncouple the negative feedback loop 
mediated by mTORC1 on mTORC2, enabling AKT phosphorylation (pAKTS473) and 
an elevation in its activity, as is evident in CLL cells (17). The role of PI3K/AKT 
mediated signaling activated downstream of BCR ligation, is well established in CLL 
survival (18-20). One mechanism utilized by AKT to promote cell survival and 
proliferation is through negative regulation of the forkhead box proteins subgroup O 
(FOXO) family of transcription factors, notably FOXO1, FOXO3a, and FOXO4, 
through phosphorylation (T24, S256, S319 on FOXO1) leading to their sequestration 
and inactivity within the cytoplasm (21). This process is key in facilitating normal B 
cell proliferation, with FOXO family members responsible for regulating a diverse 
array of cellular functions including cell cycle arrest, apoptosis and DNA-damage 
repair (21). We sought to address whether inhibition of both mTORC1 and mTORC2 
with a dual mTOR kinase inhibitor may represent a valid therapeutic approach for 
CLL. 
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Materials and Methods: 
Animals, primary cells and cell lines. Peripheral blood and LN samples were 
obtained, after informed consent, from patients with a confirmed diagnosis of CLL 
that were treatment-naïve or had received treatment but not in the preceding 3 
months. The studies were approved by the West of Scotland Research Ethics 
Service, NHS Greater Glasgow and Clyde (UK) and the Northern Ireland Biobank 
and all work was carried out in accordance with the approved guidelines. Linked 
clinical data of prognostic markers of the CLL cohorts were recorded (Suppl Table 1). 
CLL lymphocytes were isolated and used freshly or cryopreserved (22). CLL cell 
purity was ≥ 95% in all cases, determined by flow cytometry. CLL cells were cultured 
at 1x106/mL in RPMI-1640 containing 10% FBS, 50 U/mL penicillin, 50 mg/mL 
streptomycin, and 2 mM L-glutamine (complete medium; Invitrogen Ltd., Paisley, 
UK). Buffy coats were obtained after informed consent from the Scottish National 
Blood Transfusion Service (UK) and mature B cells were isolated by positive 
selection with magnetic cell sorting using anti-CD19 antibody (ab) bound to magnetic 
beads (Miltenyi, UK) and density gradient centrifugation using Histopaque (Sigma-
Aldrich Co., Poole, UK), and used fresh. MEC-1 cells (a gift from Dr. Joseph Slupsky, 
University of Liverpool) were authenticated by analysis of morphology and 
expression of appropriate CD markers by flow cytometry. MEC-1 cells were cultured 
at 1x106/mL in RPMI-1640 containing 10% FBS, 50 U/mL penicillin, 50 mg/mL 
streptomycin for up to 20 passages. Donor ICR wildtype mice were purchased from 
Harlan Laboratories (Oxon, UK) and donor B6.SJL wildtype mice and host 
recombinase activating gene-2-deficient (RAG-2−/−) and NOD-SCID-c−/− (NSG; 
provided by Dr. Karen Blyth, BICR) mice were bred in-house. All mice were 
maintained at the University of Glasgow Central Research Facilities or the Beatson 
Research Unit (Glasgow, UK), under standard animal housing conditions in 
accordance with local and home office regulations. Time-mated mice were generated 
and liver was extracted at E14.  
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BCR stimulation assay. CLL cells were incubated at 37°C in the absence (no drug 
control; NDC) or presence of AZD8055, rapamycin or ibrutinib (Stratech Scientific 
Ltd., Suffolk, UK) for 30 min. CLL cells were then stimulated with 10 μg/ml F(ab')2 
fragment anti-human IgM (Stratech Scientific Ltd.) for a set time as indicated. 
 
Flow Cytometry. Following treatment, CLL cells were harvested, stained with 
FITC/APC-conjugated Annexin V and 7-amino-actinomycin D (7-AAD). Flow 
cytometry data were acquired using a FACSCantoII flow cytometer (BD Biosciences) 
using the FACS Diva software package and analysed using the FlowJo software 
package (Tree Star, Inc., Ashland, OR) (22). Annexin V−7-AAD− cells were 
considered viable. For CLL-like mouse cells, anti-IgM-PE, anti-CD45-PerCP, anti-
CD23-PE-Cy7, anti-CD5-APC, anti-CD19-APC-Cy7 and anti-CD11b-Pacific Blue abs 
were used (BD Biosciences). For intracellular staining, surface anti-B220-PE ab 
staining was followed by fixation with cytofix/cytoperm (BD Biosciences). Cells were 
then stained with anti-pAKT S473-AF647 and pS6S235/236-V450 abs. 
 
Western blotting. Protein lysates were prepared in lysis buffer (1% Triton, 1 mM DTT, 
2 mM EDTA, 20 mM Tris pH 7.5 containing complete protease inhibitor, and 
PhosStop (Roche)), and Western blotting was carried out (22). All western blotting 
abs were sourced from Cell Signaling Technology (Hitchin, UK). Densitometry was 
performed on all the blots using Image Studio Software (LI-COR, USA). Ratios of the 
intensity levels of phosphorylated proteins over their total counterparts, or reference 
gene, as indicated were calculated. 
 
IHC and Immunofluorescence (IF). Sections for IHC were cut at 4 microns on a 
rotary microtome and dried at 37°C overnight. All IHC was performed on automated 
immunostainers (Leica BondMaX). Antigen binding sites were detected with a 
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polymer based detection system (Bond cat no. DS 9800). All sections were 
visualized with DAB, counterstained in haematoxylin and mounted in DPX.  All slides 
were reviewed by an experienced histopathologist. For IF, CLL cells were fixed with 
4% (w/v) paraformaldehyde, permeabilized in 0.25% (w/v) Triton X-100 for 10 min 
and blocked with 1% (w/v) BSA, 0.1% (v/v) Tween 20 in PBS for 30 min. Primary 
anti-FOXO1 Ab was applied for 1 h at RT and secondary anti-rabbit Ab AF488 
(Thermo Fisher Scientific) for 1 h at RT. Nuclei were stained with DAPI (Thermo 
Fisher Scientific). Z-stack images were acquired on a Zeiss-Axio Imager M1 
fluorescence microscope (Carl Zeiss AG, Jena, Germany) and deconvoluted using 
AxioVision software (Carl Zeiss AG). Object-based quantification of signal 
colocalisation (Threshold Manders’ Coefficients) between the FOXO1 and DAPI 
channels was analysed using CellProfilerTM software (Broad Institute of MIT and 
Harvard, Cambridge, MA, USA). Values for the Manders’ Coefficient range from 0 to 
1, expressing the fraction of signal intensity from one channel that exists in pixels 
above threshold signal intensity in the other channel. Signal thresholds were set by 
the Costes Auto threshold method. >360 cells were quantified/condition from each 
CLL patient (n=3).  
 
Cellular Fractionation. Nuclear, cytoplasmic and whole cell fractions were prepared 
from 1x107 MEC-1 cells per condition, using the Nuclear Extract Kit as per 
manufacturer’s instructions with modifications (Active Motif, Belgium). Briefly, when 
collecting the cytoplasmic fraction, cells were resuspended in 100 µl 1 x Hypotonic 
Buffer for 15 min, with a 1:60 ratio of detergent added before vortexing for 10 sec. 
Samples were denatured and immunoblotted as described. 
 
In vitro or in vivo B-cell/CLL-like cell generation. Haemopoietic stem and progenitor 
cells (HSPCs) isolated from E14 liver or adult bone marrow (BM) were retrovirally-
transduced using GP+E.86 packaging cells that produce retrovirus-encoding green 
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fluorescent protein (GFP) alone (MIEV-empty vector control) or dominant negative 
PKCα (PKCα-KR) as described (23). Transduced cells were cultured on OP9 cells 
that support B cell development in the presence of Flt-3L and IL-7 (10 ng/ml; 
Peprotech Ltd.) for 7 days and then either further cultured on OP9 cells in the 
presence of IL-7 only for in vitro cultures, or adoptively transferred (4x105 
cells/mouse) into RAG-2-/- or NSG mice to establish CLL-like leukemia in vivo. Blood 
sampling was performed to track disease development/progression. 
 
In vivo drug treatment. AZD8055 was formulated at 2 mg/mL in 30% Captisol (Ligand 
Pharmaceuticals, Inc., La Jolla, CA) and administered at 20 mg/kg via oral gavage 
(OG). Rapamycin was delivered once daily by intraperitoneal (ip) injection at a dose 
of 4 mg/kg dissolved in Tween-80 5.2% / PEG-400 5.2% (v/v). AZD2014 was 
prepared at 3 mg/mL in 20% Captisol (Ligand Pharmaceuticals, Inc.) and 
administered at 15 mg/kg via OG. Ibrutinib was prepared at 2.4 mg/mL in 0.5% 
methylcellulose (Sigma) and administered at 12 mg/kg via OG. After CLL-like 
disease confirmation (>0.4% GFP+CD19+ cells in the blood), mice were treated for 2 
wk with inhibitors or vehicle control and then sacrificed. BM, spleen and blood were 
collected for analyses. 
 
RNA isolation and quantitative real-time PCR. Total RNA was isolated using the 
RNeasy Mini Kit (Qiagen). Inventoried Taqman assays and PCR reagents were 
purchased from ThermoFisher (Warrington, UK). cDNA synthesis and real-time PCR 
(RT-PCR) was conducted as described previously (22). Relative gene expression 
was analyzed by the ΔΔCt method using Glucuronidase Bet (GUSB) as reference 
control and an assigned calibrator. 
 
FOXO1 activity kit (TRANS-AM). Nuclear protein lysates were isolated from 1x107 
CLL cells per condition using the Nuclear Extract Kit and an ELISA-based method, 
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TransAM (Active Motif) was used to quantify FOXO1 DNA-binding activity according 
to the manufacturer's protocol. 
 
Statistics. All statistical analysis was performed using GraphPad Prism 6 software 
(GraphPad Software Inc., CA), p values were determined by two tailed students 
paired or unpaired t-test or mixed model ANOVA on a minimum of at least 3 
biological replicates as indicated. Drug treated values are compared with the NDC 
control. Mean ± standard error of mean (SEM) is shown. *=p≤0.05; **=p≤0.01; 
***=p≤0.001; ****=p≤0.0001.  
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Results: 
Dual mTORC1/2 inhibition reduces viability of CLL samples, preferentially targeting 
poor prognostic cohorts. To determine the basal activity of mTOR in distinct cohorts 
of CLL patients, we analyzed the phosphorylation status of mTORC1 (S6S235/236; 
4EBP1T37/46; RICTORT1135) and mTORC2 (AKTS473) downstream targets in freshly 
isolated peripheral blood CLL cells, compared with B cells from healthy donors 
(Figure 1). These data indicated that phosphorylation levels of S6K target proteins 
S6 and RICTOR were reduced in del(17p) CLL cohort. Interestingly, 4EBP1T37/46 
phosphorylation was significantly elevated in the poorer prognostic del(17p) CLL 
subset indicating that mTORC1-mediated signals are differentially regulated in CLL. 
AKTS473 phosphorylation was present, but not differentially modulated in peripheral 
blood CLL cells of the patient subsets (Figure 1). Phosphorylation of S6S235/236 and 
4EBP1T37/46 were also differentially regulated when the same CLL patient cohorts 
were divided by Binet stage, with poorer prognostic (Stage C) patients exhibiting 
significantly reduced S6 phosphorylation and elevated 4EBP1 phosphorylation 
(Suppl. Figure 1). These data suggest that primary CLL cells may be preferentially 
targeted by dual mTORC1/2 inhibitors, rather than rapalogs that are allosteric 
inhibitors of mTORC1 and unable to elicit a full inhibition of mTORC1 activity (24).  
 
Treatment of primary CLL cells with increasing concentrations of AZD8055 for 48 h 
resulted in a modest but significant reduction in cell viability at clinically achievable 
concentrations (Figure 2A) (25). Analysis of patient responses to 10 nM rapamycin or 
100 nM AZD8055 compared with 1 M ibrutinib, revealed a significant and 
comparable reduction in cell viability and an elevation in apoptosis upon AZD8055 or 
ibrutinib treatment, while rapamycin did not affect CLL cell viability (Figure 2B&C) in 
agreement with previous results (26). Subdivision of prognostic subsets based on 
cytogenetics revealed that AZD8055 treatment induced significantly higher levels of 
apoptosis in poorer prognostic subsets [del(11q) or del(17p)] (Figure 2D). 
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Importantly, the viability of B and T lymphocytes derived from healthy donors was not 
significantly reduced upon treatment with AZD8055, rapamycin or ibrutinib 
highlighting the selectivity of inhibitors for CLL cells (Figure 2E).  
 
mTOR inhibition overcomes BCR-mediated survival signals. 
Stimulation of primary CLL cells with F(ab’)2 fragments, to replicate ligation of the 
BCR with soluble antigen, resulted in a modest elevation in CLL survival and Mcl-1 
protein expression, together with an elevation in phosphorylation of downstream 
targets of mTORC1 (S6S235/236) and mTORC2 (AKTS473), and increased 
phosphorylation of pERK1/2T202/Y204 (Figure 3A-C; Suppl. Figure 2). 4EBP1T37/46 
phosphorylation was not altered downstream of BCR ligation. Treatment of CLL cells 
with 100 nM AZD8055 or 10 nM rapamycin in F(ab’)2 stimulated CLL cells resulted in 
a significant inhibition of BCR-mediated survival and a reduction in Mcl-1 expression, 
which was accompanied by a reduction in S6 phosphorylation with both inhibitors, as 
expected (Figure 3A-C; Suppl. Figure 2A-C, E). AZD8055 also significantly inhibited 
4EBP1T37/46 and AKTS473 phosphorylation (Figure 3C; Suppl. Figure 2B&C). These 
studies indicate that both mTORC1 and mTORC2 regulate BCR-mediated CLL 
survival, which can be targeted by mTOR inhibitors.  
 
Dual mTOR inhibitors reduce tumor load in a CLL-like mouse model in vivo. 
To address the role of mTOR inhibition in CLL progression, in vitro-generated 
leukemic cells or mice with established leukemia from a poor-prognostic, proliferating 
CLL-like mouse model were treated with rapamycin or AZD8055 (23, 27). Analysis of 
mTOR substrate activation in PKC-KR-expressing (CLL-like) or MIEV (empty vector 
control) cells revealed elevated phosphorylation of downstream mTOR targets 
(S6S235/236, AKTS473) in CLL-like cells (Figure 3D). Moreover, rapamycin and AZD8055 
treatment inhibited phosphorylation of the appropriate targets, as noted in CLL 
patient samples (Figure 3D; Suppl. Figure 3A-C). Of note, rapamycin treatment of 
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MIEV and PKC-KR-expressing cells resulted in an elevation in AKTS473 
phosphorylation, indicating an activation of mTORC2 activity upon S6K inhibition. 
While rapamycin and AZD8055 inhibited proliferation similarly in CLL-like cells 
(Figure 3E), AZD8055-induced apoptosis selectively in PKC-KR-expressing cells, at 
a significantly higher level than measured in rapamycin-treated cells (Figure 3F), as 
observed in human CLL samples.  
 
Mice were treated once daily with either AZD8055 (20 mg/kg, OG) or rapamycin (4 
mg/kg, ip) or appropriate vehicle after confirmation of CLL-like disease development 
in blood. An inhibition of S6S235/236 and AKTS473 phosphorylation was demonstrated in 
CLL-like cells isolated from the spleen and BM of mice 2 h post the first treatment 
with AZD8055 in vivo, while rapamycin only induced a slight inhibition in S6S235/236 
phosphorylation, determined by intracellular flow cytometry (Figure 4A). Flow 
cytometric analysis of the organs removed from mice after 14 d of treatment revealed 
that AZD8055-treated mice exhibited a significant reduction in tumor burden (GFP+ 
CD19+ cells) both in terms of percentage in the spleen and BM, and cell numbers in 
the BM (Figure 4B-D). These data indicate that inhibition of mTORC1/2 results in a 
more robust inhibitory response, clearing disease more effectively, likely due to the 
combined inhibition of proliferation and induction of apoptosis (Figure 3E&F). 
 
mTORC2-mediated negative regulation of FOXO promotes CLL survival. 
A key function of AKT is the inactivation of the FOXO transcription factor family (21). 
Analysis of FOXO family member gene expression in freshly isolated CLL cells from 
peripheral blood revealed that FOXO1 and FOXO4 were significantly upregulated, 
while FOXO3 expression did not differ significantly compared to normal B cells 
(Figure 5A). Stratification of FOXO family gene expression in CLL revealed that 
FOXO1 was significantly upregulated in poorer prognostic subsets, in Binet stage C 
and patients that have previously received treatment (Suppl. Figure 4). Analysis of 
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FOXO1 expression in patient LN sections, isolated from a cross section of distinct 
prognostic subsets, revealed FOXO1 upregulation in samples carrying poor 
prognostic markers compared with LN biopsies from patients with good prognostic 
markers (Figure 5B). FOXO1 upregulation in CLL patients showed a significant 
positive correlation with Ki-67 (r2=0.620, p=0.0003; n=16), supporting an upregulation 
of FOXO1 expression in patients exhibiting progressive disease (Figure 5B).  
 
As FOXOs are widely considered to promote cell cycle arrest, the alignment of 
FOXO1 upregulation with increased Ki-67, identified morphologically in continuous 
sections suggests that while FOXO1 expression is increased, it is functionally 
inactive in CLL cells. Supporting this, established FOXO target genes were 
deregulated in CLL cells: CDKN1A (p21) and CDKN1B (p27) downregulation and 
CCND1-3 (cyclin D1-3) upregulation compared to normal controls (Figure 5C) (28). 
Interestingly, PKC-KR-CLL-like cells also exhibited elevated phosphorylation and 
expression levels of FOXO1 compared with MIEV cells (Figure 5D; Suppl. Figure 
3D&E). BCR ligation resulted in a significant upregulation of pFOXO1T24, coupled 
with a concomitant elevation in pAKTS473, phosphorylation events that were reduced 
by treating CLL cells with AZD8055 but not rapamycin (Figure 5E; Suppl. Figure 
2C&D). These data indicate that signals within the tumor microenvironment that 
stimulate mTORC2-AKT-mediated signaling may inhibit FOXO1 activity, thus priming 
CLL cells for proliferation within the lymphoid organs. IF analysis revealed that BCR 
ligation significantly enhanced cytoplasmic localisation of FOXO1, compared to 
unstimulated CLL cells (Figure 5F; Suppl. Figure 5). However, AZD8055 treatment of 
F(ab’)2-stimulated cells resulted in a significant increase in nuclear FOXO1 
localization compared to untreated (NDC) F(ab’)2-stimulated cells (Figure 5F; Suppl. 
Figure 5). These data were confirmed by sub-cellular fractionation of MEC-1 cells, 
with increased FOXO1 levels in the nuclear compartment upon AZD8055 treatment, 
being mirrored by a reduction of FOXO1 in cytoplasm (Figure 5G). These data 
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indicate that FOXO1 is a target for inactivation downstream of BCR-mediated 
AKT/mTOR activity that can be reversed by treatment with mTORC1/2 inhibitors. 
 
Dual mTOR inhibitors synergize with ibrutinib to enhance CLL cell death in vitro and 
in vivo. 
AKT is unlikely to be fully inhibited in the presence of AZD8055 due to activation of 
AKT through PI3K/PDK1 activation leading to AKTT308 phosphorylation, as indicated 
by residual pFOXO1T24 signal detected (Figure 5D). Therefore we investigated the 
impact of AZD8055 treatment on cell viability and FOXO1 phosphorylation/activity in 
combination with ibrutinib in CLL cells (29). Initially using the Chou and Talalay 
method (30), we identified synergy between 100 nM AZD8055 and 1 M ibrutinib 
(CI=0.398±0.34). We further demonstrated an enhanced induction of apoptosis, as 
indicated by an increase in AnnexinV+7-AAD- cells and an elevation in PARP 
cleavage, with both drugs in combination in the presence and absence of BCR 
ligation (Figure 6A&B). Furthermore, there was a significant reduction in the 
expression of Mcl-1 in presence of AZD8055 and ibrutinib alone and in combination 
(Figure 6B; Suppl. Figure 6).  
 
Combination of ibrutinib with AZD8055 enhanced inhibition of S6S235/236, AKTS473 and 
FOXOT24 phosphorylation in the presence of BCR stimulation (Figure 6C&D; Suppl. 
Figure 6). As expected there was a more complete inhibition of AKTS473 
phosphorylation compared with AKTT308 upon treatment with AZD8055, in the 
presence or absence of ibrutinib in unstimulated CLL cells (Figure 6C&D; Suppl. 
Figure 6).  However, BCR-mediated stimulation of AKTT308 phosphorylation was 
reduced to basal levels by AZD8055 or ibrutinib treatments (Figure 6D; Suppl. Figure 
6). Interestingly, while ibrutinib was unable to inhibit 4EBP1T37/46 phosphorylation, it 
reduced phosphorylation of ERK1/2T202/Y204 suggesting that synergy between 
AZD8055 and ibrutinib occurs through targeting of discrete signaling pathways whilst 
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inducing a more robust inhibition of the same pathways (Figure 6C&D; Suppl. Figure 
6). Importantly, BCR ligation resulted in a significant downregulation of FOXO1 
activity, which was significantly elevated upon treatment with AZD8055 and ibrutinib 
(Figure 6E), upregulating FOXO1-target gene regulation: downregulation of CCND2 
and BCL2L1 (Bcl-XL) and an upregulation of FOXO1, FOXO3 and BCL2L11 (BIM) 
(Figure 6E). Combination of AZD8055 with ibrutinib enabled a more robust effect on 
FOXO activity and FOXO-regulated genes, in the presence of BCR-mediated 
signals, with BCL2L1, CCND1 and CCND2 showing enhanced responses (Figure 
6E).  
 
To test the potential therapeutic effect of combining ibrutinib with dual mTOR 
inhibitors, mice with confirmed CLL-like disease in blood were treated once daily with 
a clinical analog of AZD8055, AZD2014 (Vistusertib (31); 15 mg/kg) or ibrutinib (12 
mg/kg) alone or in combination, or with the appropriate vehicles. Flow cytometric 
analysis of the organs removed from mice after 14 days of treatment revealed that all 
treatment arms exhibited a reduction in tumor burden. Indeed, AZD2014 treatment 
enhanced ibrutinib treatment in this aggressive CLL mouse model both in terms of 
percentage of tumor cells in the blood and organs, and cell numbers in the BM 
(Figure 6G & Suppl Figure 7). Collectively, these studies indicate that the clinical 
response elicited by ibrutinib in CLL patients may be enhanced in combination with 
dual mTOR kinase inhibitors.  
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Discussion: 
We demonstrate that AZD8055 preferentially decreased cell viability of poor 
prognostic CLL subsets in vitro generating a more robust inhibitory response in 
comparison to rapamycin, and significantly reduced tumor load in an aggressive CLL 
mouse model in vivo. This enhanced inhibitory response by AZD8055 in poor 
prognostic CLL samples may in part be due to the differential activation status of 
individual mTOR substrates observed in CLL patient samples from distinct prognostic 
subsets. In our study, stratification of the basal phosphorylation/activation status of 
mTOR substrates in fresh CLL samples revealed a differential regulation of mTORC1 
downstream substrates, with a decrease in S6 phosphorylation in poorer prognostic 
del(17p) subset. In addition to phosphorylating S6, S6K is responsible for 
phosphorylating RICTOR at T1135 and inactivating mTORC2 activity, thus 
generating a negative feedback loop between mTORC1 and mTORC2 (32). While 
our findings indicate that the inhibitory influence of S6K activity over mTORC2 is 
reduced in poorer prognostic CLL, AKT phosphorylation is not elevated in the poor 
prognostic samples, suggesting that a reduction in mTORC1-S6K activity may prime 
CLL cells to respond more robustly to microenvironmental stimulation. We also noted 
an upregulation in 4EBP1 phosphorylation in poorer prognostic CLL patient subsets, 
which would result in a reduction in binding to the mRNA cap-binding protein eIF4E. 
This event could enable the translation of proteins including Mcl-1 and c-Myc (33, 
34), which are associated with CLL progression (35, 36).  
 
Differential mTOR substrate activation status observed in CLL cells may affect the 
subsequent response to mTOR inhibitors, with CLL survival of poor prognostic 
patient samples exhibiting higher sensitivity upon treatment with mTORC1/2 
inhibition, compared with rapamycin. Indeed, rapamycin is unable to fully block 
phosphorylation of 4EBP1 (24), and releases the mTORC1 feedback inhibition on 
mTORC2 enabling reactivation of AKT (17), suggesting that the efficacy of 
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rapamycin is limited in poor-prognostic patients with reduced mTORC1-S6K activity. 
This is supported by recent data demonstrating an everolimus-sensitive cohort of 
CLL patients that carry good prognosis (mutated IgVH), that rely on mTORC1 
signaling in a BCR independent manner (37). These studies highlight potential 
reasons for everolimus only demonstrating modest responses in CLL patients in 
clinical trial (16), and suggest that dual mTORC1/2 inhibition may provide a more 
robust inhibitory response, particularly in high-risk CLL patients.  
 
Selectivity of AZD8055 for mTOR was demonstrated in CLL cells, with drug 
treatment potently inhibiting the mTORC2 phosphorylation site, AKTS473 while not 
affecting AKTT308 phosphorylation in unstimulated CLL cells. These studies indicate 
that AZD8055 does not inhibit PDK1 activity. Of note, upon BCR stimulation of CLL 
cells, treatment with AZD8055 or ibrutinib reduced AKTT308 phosphorylation to basal 
levels observed in unstimulated CLL cells. Reduction in phosphorylation of AKTT308  
has been reported in other cell lines upon treatment with AZD8055 (38), and with 
additional mTOR kinase inhibitors such as PP242 (39). This is likely due a reduction 
in the ability of PDK1 to phosphorylate the T308 site on AKT when S473 
phosphorylation is inhibited.  
 
Potency of AZD8055 and rapamycin in vivo was tested by assessing the 
phosphorylation status of S6S235/236 and AKTS473 in the spleen and BM. We show a 
trend towards significance, more marked with AZD8055 than rapamycin. Referring to 
clinical trials with AZD8055 or everolimus, the time to maximal serum concentration 
for both drugs is similar (0.5-2 hr) when dosed orally (25, 40). Rapalogs have a 
longer half-life than AZD8055, which suggests that given the distinct routes of drug 
delivery in our model, it may have been appropriate to analyse the activation status 
of mTOR substrates after >1 dose to enable a steady state to be reached. However, 
we were concerned that the tumor load would be reduced to the point that it would be 
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difficult to gain a statistically robust read-out of S6S235/236 and AKTS473 
phosphorylation status. 
 
One target of mTORC2-AKT-mediated signaling is the FOXO family of transcription 
factors that play a pivotal role in a multitude of cellular homeostatic processes in 
specific cell contexts in response to a plethora of environmental stimuli including 
nutrients, insulin and growth factors (21, 41). FOXO1 has been shown to play a 
critical role in the regulation of glucose and fatty acid metabolism in skeletal muscle, 
liver and heart, an exhibits reduced activity in adipocytes isolated from diabetic 
patients (21, 42).  Interestingly, acute mTOR inhibition with AZD8055 treatment 
results in suppression of glycolysis and a reduction in insulin sensitivity of glucose 
uptake in muscle (43). While recent studies revealed an essential role for FOXOs in 
cancer progression, in the maintenance of leukemia-initiating cells in myeloid 
leukemias (AML and CML), and in promotion of breast tumor invasion (44-46), 
FOXOs were originally considered to behave as tumor suppressors as conditional 
triple deletion of FOXO1/3/4 in adult mice resulted in the development of thymic 
lymphomas and hemangiomas (47). A number of studies support the role of FOXO1 
as a tumor suppressor in B cell malignancies: inactivating point mutations in FOXO1 
have been identified in non-Hodgkin lymphoma (46, 48); FOXO1 expression is often 
reduced in Hodgkin lymphoma, mediastinal B cell lymphoma and in 20% of GCB-
DLBCL patients compared with normal B lymphocytes (49, 50). These findings 
indicate a deregulation of FOXO1 by distinct mechanisms in B cell malignancies. We 
demonstrate that FOXO1 expression is significantly upregulated in primary CLL cells 
from peripheral blood and LN biopsies of patients exhibiting poor prognosis, 
positively correlating with Ki-67 in LN biopsies. These findings suggest that FOXO1 
may represent a novel target and/or biomarker for progressive disease.  
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While upregulated in CLL cells, FOXO1 appears to be functionally inactive, as 
indicated by its cytoplasmic localization and deregulation of FOXO-target genes 
(CDKN1A, CDKN1B, CCND1-3), downstream of tumor microenvironmental signals 
generated in vivo. We demonstrate a significant upregulation in FOXO1T24 
phosphorylation, and downregulation in FOXO1 activity, in CLL cells upon BCR 
crosslinking. FOXO1T24 phosphorylation is an AKT-mediated phosphorylation event 
that enables FOXO binding to 14-3-3 proteins and subsequent export to the 
cytoplasm. FOXOs are negatively regulated by key oncogenic signals including the 
PI3K/AKT/mTOR pathways, which are upregulated in CLL cells downstream of BCR- 
and CD40-ligation within the tumor microenvironment (22, 30). Inactivation of FOXO 
proteins downstream of these pathways, enabled by the reduced negative regulation 
of mTORC2 by mTORC1-S6K, may contribute towards CLL pathogenesis. Of note, 
BCR-mediated inactivation of FOXO1 is partially alleviated by treating CLL cells with 
AZD8055, through inhibition of mTORC2-AKT-mediated signals, promoting CLL cell 
death. A recent study using the Syk inhibitor, R406 to inhibit tonic BCR signaling in 
DLBCL supports the role of FOXO1 in mediating cytotoxic and anti-proliferative 
activities in B cell malignancies (51).  
 
While targeted therapies, such as ibrutinib, have a positive impact on the survival 
rates of high-risk CLL patients, resistance mutations either in BTK or PLC2 arise in 
response to treatment, underlining the importance of developing novel treatment 
strategies for this patient subgroup (13). Combination therapies offer the potential to 
reduce the ability of the cancer cell to adapt to treatments by targeting distinct 
signaling components within the cell and mTOR represents an ideal target. We 
establish that FOXO1 function was further enhanced on combination of AZD8055 
with ibrutinib, as indicated by improved inhibition of mTORC1/2-mediated signals. 
This in turn led to significantly reduced FOXO1T24 phosphorylation, particularly upon 
BCR ligation and significantly increased FOXO1 activity and the subsequent FOXO-
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mediated transcription programme. Furthermore, treatment of CLL-bearing mice with 
AZD2014 (in clinical trial in solid tumors and DLBCL) enhanced the ability of ibrutinib 
to reduce tumor load. Ibrutinib and AZD2014 have been demonstrated to synergize 
in DLBCL (ABC subtype) cell lines and subtypes of primary CNS lymphoma, to 
induce enhanced apoptosis (52, 53). These studies suggest that when BCR signaling 
plays a central role in disease pathogenesis such as CLL, combinations of BCR 
antagonists with mTOR kinase inhibitors may represent a promising treatment, due 
to the enhanced ability to overcome key microenvironmental signals. mTOR 
inhibitors have also been shown to synergize with BH3 mimetics in small-cell lung 
cancer by reducing Mcl-1 expression and enabling BIM-induced apoptosis: 
Venetoclax (ABT-199), which is used to treat relapsed CLL patients that are 
refractory to BCR antagonists, synergizes with NVP-BEZ235 (PI3K/mTOR inhibitor) 
and idelalisib (PI3K inhibitor) by downregulating Mcl-1 in DLBCL cell lines (54). 
Collectively, our studies demonstrate that targeting mTORC1/mTORC2 shows 
promise as a future therapy for high-risk CLL patients, and highlights the importance 
of inhibiting mTORC2-AKT-mediated signals to enable activation of FOXO1-
mediated molecular braking system. In particular, dual mTORC1/2 inhibitors coupled 
with current therapies suitable for high-risk CLL patients may offer a rational 
combination to increase the proportion of minimal residual disease negative 
remissions, thus reducing the development of CLL clones with resistance mutations.  
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Figure Legends 
Figure 1: Downstream mTORC1/mTORC2 substrates are differentially 
regulated in primary CLL cells isolated from distinct prognostic subgroups. 
Protein lysates were generated from freshly-isolated B lineage cells (CLL/mature B 
cells) purified from peripheral blood of CLL patients or healthy donors. CLL patients 
were stratified based on cytogenetic abnormalities to indicate prognosis: 
normal/del(13q) (good), del(11q), del(17p) (poor). A. Western blotting was performed 
to determine the phosphorylated levels of mTORC1 downstream targets (S6S235/236, 
4EBP1T37/46 and RICTORT1135) and mTORC2 substrate (AKTS473) together with 
GAPDH as a loading control. Representative n=2 for each subset shown. B. 
Densitometry ratios of phosphorylated proteins vs. GAPDH from the blot are shown. 
n≥6 for each patient subset, n≥4 healthy controls. 
 
Figure 2: AZD8055 treatment selectively and significantly reduces primary CLL 
cell viability preferentially in poor prognostic subsets. 
A. Primary CLL cells were incubated with increasing concentrations of AZD8055 or 
left untreated for 48 h (n=12 CLL patient samples). Cell viability was analyzed by flow 
cytometry, with the percentage of viable cells assessed as Annexin V-7-AAD-; B. Cell 
viability was compared upon treatment of primary CLL cells with 100 nM AZD8055 
(AZD; blue), 10 nM rapamycin (RAP; red) or 1 M ibrutinib (IB; pink) for 48 h, 
compared with NDC (white), (n=15); C. The level of apoptosis (Annexin V+7-AAD-) 
was compared upon treatment of primary CLL cells with 100 nM AZD8055, 10 nM 
rapamycin or 1 M ibrutinib for 48 h, relative to NDC. p values generated by a paired 
two tailed t test (n=15). Inset: Western blotting was performed to show the levels of 
PARP cleavage (cPARP) in primary CLL cells treated with 100 nM AZD8055, 10 nM 
rapamycin or 1 M ibrutinib for 48 h, or left untreated (NDC). GAPDH is included as a 
loading control. D. The level of apoptosis induced in primary CLL cells treated with 
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100 nM AZD8055 minus background (NDC) was compared between cytogenetic 
subgroups: good (Norm/del(13q)) vs poor (del(11q) or (17p)). p value generated by 
an unpaired two tailed t test (n≥7 per subgroup). E. Freshly-isolated peripheral blood 
mononuclear cells from healthy donors, were incubated with 100 or 300 nM 
AZD8055, 10 nM RAP or 1 M IB for 48 h, compared with NDC. Cell viability of B 
(CD19+) and T (CD3+) populations was assessed, as indicated (n=6). 
 
Figure 3: mTOR inhibition with AZD8055 or rapamycin treatment overcomes 
the pro-survival effect of BCR crosslinking in primary CLL cells and in a poor 
prognostic CLL mouse model in vitro.  
CLL cells were pre-treated with 100 nM AZD8055 (AZD) or 10 nM rapamycin (RAP), 
or left untreated (NDC) and then BCR was ligated with addition of F(ab’)2 fragments 
for 1 or 48 h or left unstimulated (US), as indicated. A. Cell viability was analyzed by 
flow cytometry after 48 h incubation (n=14). p value generated by a paired two tailed 
t test; B. Western blotting of the anti-apoptotic protein Mcl-1 was performed after 48 
h incubation; C. Western blotting was performed to determine the phosphorylated 
levels of mTORC1 downstream targets (S6S235/236 and 4EBP1T37/46) and mTORC2 
substrate (AKTS473) and pERK (pERK1/2T202/Y204) together with the respective total 
proteins and a GADPH loading control, 1 h post drug treatment; D. MIEV- or PKC-
KR-HSPC-derived mouse cells from OP9 co-cultures (post d14) were treated for 24 h 
in the presence of 100 nM AZD8055 or 10 nM rapamycin or left untreated as 
indicated. Western blotting was performed to determine the phosphorylated levels of 
mTORC1 downstream targets (S6S235/236 and 4EBP1T37/46) and mTORC2 substrate 
(AKTS473) together with the respective total proteins or GAPDH. E. 5 x 104 d15 MIEV- 
or PKC-KR-HSPC-derived cells were plated on OP9 co-cultures and treated for 48 
h in the presence of 200 nM AZD8055 or 10 nM rapamycin or left untreated as 
indicated, and cells were counted. Data are represented as mean (± SEM) of at least 
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3 biological replicates. F. Apoptosis was analyzed by flow cytometry after 48 h 
treatment of MIEV- or PKC-KR-HSPC-derived cells. Annexin V+7AAD- cells 
represent early apoptotic cells. Data are represented as mean (± SEM) of at least 4 
biological replicates. Significance was determined by a 2-way ANOVA. 
 
Figure 4: Treatment of leukemic mice with AZD8055 leads to a significant 
reduction in CLL tumor load in vivo. 
A. After confirmation of a population of CLL-like cells in the blood (≥ 5% 
GFP+CD19+), mice were dosed with 20 mg/kg AZD8055, 4 mg/kg rapamycin or 
respective vehicle controls for 2 h. Thereafter, cells were isolated from BM and 
spleen (SP) and levels of AKTS473 and S6S235/235 phosphorylation was determined on 
GFP+B220+ cells with intracellular flow cytometric analysis. Data are represented as 
mean fluorescence intensity (MFI) ratio of stained sample over isotype control (n=6). 
p value was generated using the student’s unpaired t-test. B. After confirmation of a 
population of CLL-like cells in the blood (≥ 0.4% GFP+CD19+), mice were dosed daily 
with 20 mg/kg AZD8055 (OG), 4 mg/kg rapamycin (IP) or respective vehicle control 
for up to 14 days. Thereafter, blood, BM and spleen were analyzed for leukemic 
burden. Representative flow cytometric analyses of vehicle-, AZD8055- or 
rapamycin-treated mice are shown. Data shown are analyzed for CLL cell markers, 
CD19 and GFP after live and size (FSC/SSC) and CD45+ gating. The percentage of 
GFP+ CLL-like cells within the total population is shown; C. Percentage and D. 
Number of GFP+ CD45+CD19+ cells are shown in treated mice in the organs 
indicated. All data shown are the mean (± SEM) of 5 individual mice. p values were 
generated using the student’s unpaired t-test. 
 
Figure 5: FOXO1 is reactivated with AZD8055 treatment upon BCR ligation.  
A. RNA was isolated from fresh CLL samples (n=28) and qPCR was performed to 
measure expression levels of FOXO gene family members. A scatterplot of gene 
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expression is shown, each symbol denotes an individual CLL sample. Bars indicate 
the mean fold change in gene expression relative to 10 healthy B cell samples ± 
SEM; B. IHC was performed on LN biopsies from CLL patients of favourable (n=11) 
and poor prognosis (n=9). Representative images are shown for FOXO1 staining. 
FOXO1 and Ki-67 stained LN sections were scored and compared between 
favourable and poor prognostic CLL samples; C. qPCR (from A; n=28) was performed 
to measure expression levels of FOXO target genes as indicated. Bars indicate the 
mean fold change in gene expression relative to 10 healthy samples ± SEM; D. 
Protein lysates were generated from in vitro co-cultures of MIEV- or PKC-KR-
transduced mouse cell cultures. Western blotting compared the phosphorylated and 
expression levels of FOXO1T24 and total FOXO1 respectively, compared with loading 
control GAPDH. E-G. CLL cells were pre-treated with 100 nM AZD8055, 10 nM 
rapamycin, or left untreated (NDC) as indicated. BCR was ligated with addition of 
F(ab’)2 fragments for 1 h or US. E. Western blotting assessed phosphorylated levels 
of FOXO1T24 and AKTS473 and expression levels of total FOXO1 and AKT. GAPDH is 
included as a loading control; F. CLL cells were fixed and permeabilized and stained 
with anti-FOXO1 Ab (green) and DAPI (blue). Top: A representative 100x 
deconvoluted image of primary CLL cells is shown (n=3); Scale bar, 5 µm. Bottom:  
Analyses of the IF images (x40) were performed in CellProfiler to quantify co-
localisation of FOXO1 fluorescent intensity levels with DAPI (nuclear stain) in 
individual cells from individual CLL patients. The average Threshold Manders’ 
Colocalisation Coefficient for each condition from 3 individual CLL patient samples is 
shown. G. MEC-1 cells were pre-treated for 30 min with 100 nM AZD8055 (AZD) or 
left untreated (NDC) as indicated and then BCR was ligated for 1 or left US. 
Thereafter nuclear and cytoplasmic fractions were prepared and immunoblotted 
alongside whole cell lysates (WCL). Western blotting shows the levels of FOXO1, 
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lamin A/C (nuclear) and -tubulin (cytoplasmic) proteins in each condition. 
Representative blot shown of n=3 biological replicates. 
 
Figure 6: Combination of AZD8055 with Ibrutinib further increases FOXO1 
function upon BCR ligation in primary CLL cells. 
CLL cells were pre-treated for 30 min with 100 nM AZD8055 (AZD) or 1 M ibrutinib 
(IB) alone or in combination, or left untreated (NDC) as indicated and then BCR was 
ligated with addition of F(ab’)2 fragments for 1, 24 or 48 h or left US, as indicated. A. 
Cell viability was analyzed by flow cytometry after 48 h incubation (n=7). p value 
generated by a paired two tailed t test; B. Western blotting was performed to 
determine the level of PARP cleavage and Mcl-1 expression after 48 h incubation 
(n=4). GAPDH is included as a loading control; C&D. Western blotting was 
performed to determine the phosphorylated levels of FOXO1T24/FOXO1 (C), 
AKTS473/AKT (C), S6S235/236/S6 (D), 4EBP1T37/45/4EBP1 (D), AKTT308/AKT (D) and 
pERK1/2T202/Y204/ERK1/2 (D) (n≥4); E. Nuclear lysates were generated from CLL cells 
and DNA binding activity of FOXO1 was assessed in each condition, as indicated 
(n=5). Statistical significance calculated using a student’s t test; F. RNA was 
prepared from CLL cells (n≥8 individual patient samples) treated with AZD8055 (AZ) 
or ibrutinib (IB) alone or together (CO) in the presence or absence of BCR ligation 
after 24 h incubation as indicated, and mRNA expression levels of FOXO1, FOXO3, 
CCND1-2, BCL2L1, and BCL2L11 were determined by qPCR. Each gene is 
expressed relative to GUSB reference gene and calibrated to ND US or ND F(ab’)2 
samples. Data are mean ± SEM, and p values generated by a paired two-tailed t-
test. G. After confirmation of a population of CLL-like cells in the blood, mice were 
dosed daily with 15 mg/kg AZD2014 (OG), 12 mg/kg ibrutinib (OG) alone or in 
combination, or respective vehicle control for up to 14 days. Thereafter, blood, BM 
and spleen were analyzed for leukemic burden. The average percentage of GFP+ 
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CLL-like cells in the blood is shown for each treatment arm (top); Cell number of 
GFP+ CD45+CD19+ population is shown in treated mice in the BM (middle) and SP 
(bottom). All data shown are the mean (± SEM) of 5 individual mice. p values were 
generated using the student’s unpaired t-test. 
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